UC Davis Veterinary Clinical Trials

Assessing a Stem Cell Treatment for Myasthenia Gravis (MG) in Dogs

Help us treat dogs with Myasthenia Gravis!

Myasthenia Gravis (MG) is a rare neuromuscular disease that is the result of an immune system attack on structures critical for nerve to muscle signaling. Clinical signs include generalized weakness and muscle weakness around the eyes, limbs or airways. There is no cure though some dogs will go into spontaneous remission. Novel stem cell therapies offer new hope for dogs with MG. For this clinical trial, we hope that adding stem cell treatment along with standard pharmaceutical treatment and care for MG will improve symptoms of the disease.

Stem Cell Study

Assessing a New Drug to Treat Heart Failure in Dogs with Myxomatous Mitral Valve Disease

Please talk to your veterinarian or bring your dog to the UC Davis VMTH Emergency Room for evaluation!

Myxomatous mitral valve disease is the most common cardiac disease and the leading cause of congestive heart failure in dogs. Reducing blood pressure is one strategy to help manage these patients. By reducing blood pressure, the heart can move blood forward more effectively, reducing fluid accumulation in the lungs that can result from this condition. However, available medications for this health emergency are extremely limited and currently available drugs often have extreme price volatility, low availability or unwanted side effects. Researchers will conduct a small clinical trial to evaluate the use of a new drug clevidipine to reduce blood pressure in client-owned dogs admitted to hospital. Finding a safe, affordable alternative drug that is readily available may help improve survival of critically ill canine patients requiring urgent care for heart failure.

Drug - Treatment